Johnson & Johnson
JNJ: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| Xr? | LOCK|fJ! | LOCK|hQ<p&hZ |
Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility; Maintaining Our FVE
J&J's revenue grew 6.6% to $25.3 billion in the second quarter, driven by 7.8% growth in Innovative Medicine and 4.5% in MedTech. Management increased the midpoint of 2026 guidance by $300 million on the top line and $0.13 on the bottom line. Shares fell 2% intraday on July 15.
